good points longx. I suppose the lack of cash is the reason MNK was able to defer so much of the potential into the CVR rather than paying more in cash for the shares. I agree that with MNK's resources the drug has a better chance of coming to market. I'm guessing that the increasing share price ahead of the deadline indicates the market believes there is growing chance of the deal being finalized.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.